CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 7105 result(s)

Consultation for Patients on the Deliberative Appraisal Process at CADTH

Event Date: February 11, 2021
Result type: Events

The top three principles for the deliberative process identified by the Health Technology Assessment International 2020 Global Policy Forum were transparency, inclusivity, and impartiality. CADTH has worked with a few patient groups to create a two-part consultation to support wide participation: first, an education session — How CADTH Expert C...

How CADTH Expert Committees Deliberate

Event Date: February 4, 2021
Result type: Events

CADTH has three expert committees that provide recommendations to publicly funded drug programs, health ministries, and health authorities on the appropriate use of drugs, medical devices, and clinical interventions: CADTH pan-Canadian Oncology Drug Review Expert Review Committee (pERC): cancer drugs CADTH Canadian Drug Expert Committee (CDE...

There’s Always Evidence…

Event Date: January 19, 2021 - February 9, 2021
Result type: Events

There’s solid agreement that decisions in health care that are informed by hard facts are likely to be better than decisions made based on gut instinct or something your brother’s best friend’s second cousin says his grandmother’s neighbour told him. Systematic reviews and meta-analyses are regarded as the gold standard for evidence, but they ar...

von Willebrand Factor [recombinant] (Vonvendi)

Last Updated: January 14, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: von Willebrand Factor [recombinant]
Indications: ​Indicated for: Treatment and Control of bleeding episodes in adults (age ≥18) diagnosed with von Willebrand Disease (VWD).Perioperative management of bleeding in adults (age ≥18) diagnosed with VWD

  • Brand Name: Vonvendi
  • Manufacturer: Shire Pharma Canada ULC, now part of Takeda
  • Project Number: ST0639-000
  • Project Status: Active
  • Submission Type: Initial

luspatercept (Reblozyl)

Last Updated: December 24, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: luspatercept
Indications: For the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia associated with beta(β)-thalassemia

  • Brand Name: Reblozyl
  • Manufacturer: Celgene Inc. / Bristol-Myers Squibb Canada Co.
  • Project Number: SR0669-000
  • Project Status: Active
  • Submission Type: Initial

liraglutide (Saxenda)

Last Updated: December 24, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: liraglutide
Indications: Saxenda® (liraglutide) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia) and who have failed a previous weight management intervention.

  • Brand Name: Saxenda
  • Manufacturer: Novo Nordisk Canada Inc.
  • Project Number: SR0668-000
  • Project Status: Active
  • Submission Type: Initial

Levetiracetam (pdp-levETIRAcetam)

Last Updated: December 22, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Levetiracetam
Indications: Adjunctive therapy for: Adults management of patients with epilepsy who are not satisfactorily controlled by conventional therapyPediatrics partial onset seizures with or without secondary generalization in adolescents, children and infants from 1 month of age with epilepsy. myoclonic seizures in adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. primary generalized tonic-clonic seizures in adolescents from 12 years of age with Idiopathic Generalized Epilepsy.

  • Brand Name: pdp-levETIRAcetam
  • Manufacturer: Pendopharm, a division of Pharmascience Inc.
  • Project Number: SR0653-000
  • Project Status: Active
  • Submission Type: Initial

vedolizumab (Entyvio)

Last Updated: December 24, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: vedolizumab
Indications: For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to immunomodulators or a TNFα antagonist; or have had an inadequate response, intolerance, or demonstrated dependence on corticosteroids.

  • Brand Name: Entyvio
  • Manufacturer: Takeda Canada Inc.
  • Project Number: SR0647-000
  • Project Status: Active
  • Submission Type: Initial

dapagliflozin (Forxiga )

Last Updated: January 6, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: dapagliflozin
Indications: ​Forxiga is indicated in adults, as an adjunct to standard of care therapy, for the treatment of heart failure with reduced ejection fraction (HFrEF) to reduce the risk of CV death, hospitalization for heart failure and urgent heart failure visit, and to improve heart failure symptoms.

  • Brand Name: Forxiga
  • Manufacturer: AstraZeneca Canada Inc.
  • Project Number: SR0642-000
  • Project Status: Active
  • Submission Type: Initial

onasemnogene abeparvovec (Zolgensma)

Last Updated: December 21, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: onasemnogene abeparvovec
Indications: ​Zolgensma is an adeno-associated virus (AVV) vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.

  • Brand Name: Zolgensma
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SG0649-000
  • Project Status: Active
  • Submission Type: Initial